Evidence map›Paper›PMID 31138333›Full record

ArticleJournal for immunotherapy of cancer2019

Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro.

Brooke Benner, Luke Scarberry, Lorena P Suarez-Kelly, Megan C Duggan, Amanda R Campbell, Emily Smith, Gabriella Lapurga, Kallie Jiang, Jonathan P Butchar, Susheela Tridandapani and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07638982 (An Open-label, Phase I Trial, With an Expansion Cohort), which is not on this map. Cited by 113 papers.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07638982 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)

TypeinterventionalSponsorNorthside Hospital, Inc.Ran2026 to 2029Enrolled29ConditionsDiffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), High-Grade B-Cell Lymphoma, NosArmsAxatilimab
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 179 citations in OpenAlex.

  1. Oncoimmunology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. SSTNSignal transduction and targeted therapy · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Brooke BennerComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Luke ScarberryComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Lorena P Suarez-KellyDivision of Surgical Oncology, The Ohio State University, N924 Doan Hall, 410 W. 10th Avenue, Columbus, OH, 43210, USA.
Megan C DugganComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Amanda R CampbellComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Emily SmithComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Gabriella LapurgaComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Kallie JiangComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Jonathan P ButcharComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Susheela TridandapaniComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
John Harrison HowardDivision of Surgical Oncology, The Ohio State University, N924 Doan Hall, 410 W. 10th Avenue, Columbus, OH, 43210, USA.
Robert A BaiocchiDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA.
Thomas A MaceComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
William E CarsonComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. william.carson@osumc.edu.
The Ohio State University · USComprehensive Blood & Cancer Center · USU-M Rogel Cancer Center

Funding

TWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2002 to 2016
$29.6M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
ONOCOLOGY TRAINING GRANTT32CA009338 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C., POLLOCK, RAPHAEL E. · 1985 to 2018
$8.3M
NCATS NIH HHS UL1 TR002733NCI NIH HHS P01 CA095426NCI NIH HHS T32 CA009338
6 · The paper itself

Abstract

backgroundTumor-associated macrophages (TAM) are expanded and exhibit tumor-promoting properties within the tumor microenvironment. Current methods to study TAM have not been replicated across cancer types and often do not include exogenous growth factors from the tumor, a key factor in TAM differentiation in vivo.

methodsIn this study, an in vitro method to generate monocyte- derived TAM using tumor- conditioned media (TCM) and a cytokine cocktail containing IL-4, IL-10, and M-CSF was utilized to study the phenotype, morphology, and function of TAM across multiple cancer types. TCM was generated from two breast cancer cell lines and an Epstein-Barr virus-positive lymphoma cell line. The properties of in vitro generated TAM were compared to in vitro generated M1 and M2- like macrophages and TAM isolated from patients with cancer.

resultsTAM generated in this fashion displayed an increase in CD163/CD206 co-expression compared to M2- like macrophages (87 and 36%, respectively). TAM generated in vitro exhibited increased transcript levels of the functional markers IL-6, IL-10, CCL2, c-Myc, iNOS, and arginase compared to in vitro generated M2-like macrophages. Functionally, in vitro generated TAM inhibited the proliferation of T cells (47% decrease from M1-like macrophages) and the production of IFN-γ by natural killer cells was inhibited (44%) when co-cultured with TAM. Furthermore, in vitro generated TAM secreted soluble factors that promote the growth and survival of tumor cells.

conclusionsLimited access to patient TAM highlights the need for methods to generate TAM in vitro. Our data confirm that monocyte-derived TAM can be generated reliably using TCM plus the cytokine cocktail of IL-4, IL-10, and M-CSF. Given the ability of TAM to inhibit immune cell function, continued study of methods to deplete or deactivate TAM in the setting of cancer are warranted.

Indexed as

Cell DifferentiationCell Line, TumorCell Transformation, NeoplasticCulture Media, ConditionedHumansImmunotherapyMacrophagesTumor MicroenvironmentCulture Media, ConditionedCancerImmunotherapyIn vitro generationTumor-associated macrophages

Identifiers

PMID31138333
PMCPMC6540573
OpenAlexW2947216697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.